Skip to main content
Erschienen in: Die Diabetologie 5/2021

23.06.2021 | Typ-1-Diabetes | Journal Club

Erhebliche Verbesserungen akuter Diabeteskomplikationen durch die Einführung eines Flash-Glukose-Monitorings

Die RELIEF-Studie

verfasst von: Dr. Michael Jecht

Erschienen in: Die Diabetologie | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Auszug

Roussel R, Riveline J‑P, Vicaut E et al (2021) Important drop rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the RELIEF study. Diabetes Care 44. https://​doi.​org/​10.​2337/​dc20-1690
Literatur
1.
Zurück zum Zitat Charleer S, De Block C, Van Huffel L et al (2020) Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care 43:389–397CrossRef Charleer S, De Block C, Van Huffel L et al (2020) Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care 43:389–397CrossRef
2.
Zurück zum Zitat Tyndall V, Stimson RH, Zammitt NN et al (2019) Marked improvement in HbA1c following commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia 62:1349–1356CrossRef Tyndall V, Stimson RH, Zammitt NN et al (2019) Marked improvement in HbA1c following commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia 62:1349–1356CrossRef
3.
Zurück zum Zitat Bezin J, Duong M, Lassalle R et al (2017) The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf 26:954–962CrossRef Bezin J, Duong M, Lassalle R et al (2017) The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf 26:954–962CrossRef
4.
Zurück zum Zitat Halbron M, Bourron O, Andreelli F et al (2019) Insulin pump combined with flash glucose monitoring: a therapeutic option to improve glycemic control in severely nonadherent patients with type 1 diabetes. Diabetes Technol Ther 21:409–412CrossRef Halbron M, Bourron O, Andreelli F et al (2019) Insulin pump combined with flash glucose monitoring: a therapeutic option to improve glycemic control in severely nonadherent patients with type 1 diabetes. Diabetes Technol Ther 21:409–412CrossRef
5.
Zurück zum Zitat Vantyghem MC, Press M (2006) Management strategies for brittle diabetes. Ann Endocrinol 67:287–296CrossRef Vantyghem MC, Press M (2006) Management strategies for brittle diabetes. Ann Endocrinol 67:287–296CrossRef
6.
Zurück zum Zitat Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R (2016) Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 388:2254–2263CrossRef Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R (2016) Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 388:2254–2263CrossRef
7.
Zurück zum Zitat Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G (2017) Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 8:55–73CrossRef Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G (2017) Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 8:55–73CrossRef
8.
Zurück zum Zitat Detournay B, Halimi S, Robert J, Deschaseaux C, Dejager S (2015) Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. Vasc Health Risk Manag 11:417–425PubMedPubMedCentral Detournay B, Halimi S, Robert J, Deschaseaux C, Dejager S (2015) Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. Vasc Health Risk Manag 11:417–425PubMedPubMedCentral
9.
Zurück zum Zitat Zhong VW, Juhaeri J, Cole SR et al (2017) Incidence and trends in hypoglycemia hospitalization in adults with type 1 and type 2 diabetes in England, 1998–2013: a retrospective cohort study. Diabetes Care 40:1651–1660CrossRef Zhong VW, Juhaeri J, Cole SR et al (2017) Incidence and trends in hypoglycemia hospitalization in adults with type 1 and type 2 diabetes in England, 1998–2013: a retrospective cohort study. Diabetes Care 40:1651–1660CrossRef
Metadaten
Titel
Erhebliche Verbesserungen akuter Diabeteskomplikationen durch die Einführung eines Flash-Glukose-Monitorings
Die RELIEF-Studie
verfasst von
Dr. Michael Jecht
Publikationsdatum
23.06.2021
Verlag
Springer Medizin
Erschienen in
Die Diabetologie / Ausgabe 5/2021
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI
https://doi.org/10.1007/s11428-021-00788-y

Weitere Artikel der Ausgabe 5/2021

Die Diabetologie 5/2021 Zur Ausgabe

DDG Praxisempfehlungen

Gesundheits-Pass Diabetes

Mitteilungen des BDI

Mitteilungen des BDI

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.